Oxylanthanum Carbonate PDUFA Date (Unicycive Therapeutics)
FDA PDUFA decision date for Oxylanthanum Carbonate is June 29, 2026. Developed by Unicycive Therapeutics. Indication: Hyperphosphatemia in CKD dialysis patients. Current status: Verifying.
Indication
Hyperphosphatemia in CKD dialysis patients
Regulatory details
- Company: Unicycive Therapeutics
- Therapeutic area: Nephrology
- Application type: NDA
- Review type: Standard
- PDUFA date: 2026-06-29
- Outcome: Pending